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I/II trial to determine the safety and efﬁcacy of a combination of
arsenic trioxide, melphalan and ascorbic acid (AA) as preparative
regimen in patients undergoing high-dose therapy (HDT) and autol-
ogous hematopoietic progenitor cell transplantation for multiple my-
eloma (MM). We also assessed the impact ATO levels on melphalan
pharmacokinetics (PK), engraftment and toxicity.
Methods: Forty-eight patients with secretory myeloma (23 females,
25 males; median age: 54, range: 35-70) were treated between 4/04
and 8/05. All patient received melphalan 100 mg/m2 IV on days -4
and -3 and AA 1000 mg/day IV on days -9 to -3. Patients were
randomized to 3 arms; no ATO (arm 1), ATO 0.15 mg/kg IV on days
-9 to -3 (arm 2) and ATO 0.25 mg/kg IV on days -9 to -3 (arm 3).
Twelve patients had a prior autograft. Median CD34 cells dose in-
fused was 4.5  106/kg (range 2.3 -10.9).
Results: Patients in all 3 arms were evenly matched.With a median
F/U of 17 months (range 6-29) post autograft, no dose-limiting
toxicity or non-relapse mortality was seen. Toxicity was limited to
grade I or II nausea, vomiting and diarrhea and was similar in all 3
arms. Melphalan PK was not altered by ATO pretreatment. Median
time to neutrophil engraftment (ANC 500/ dl) was 9 days, with no
engraftment failures or delays in the ATO arms. CR rate for the entire
group was 23%, and overall response rate (ORRCR  PR) was
75%. Progression-free survival (PFS) and overall survival (OS) after
17-month F/U were 68% and 82%, respectively. There was no
signiﬁcant difference in CR, ORR, PFS or OS between the 3 arms (p
 0.9, 0.9, 0.5 and 0.6, respectively). A prior autologous transplant (p
 0.02) and abnormal cytogenetics at transplant (p  0.04) were
associated with a signiﬁcantly shorter remission.
Conclusions: ATO  melphalan  ascorbic acid is a safe,
effective and well tolerated preparative regimen for patients with
multiple myeloma undergoing an autotransplant. A prior autograft
and abnormal cytogenetics are associated with worse outcome.
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AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ELDERLY PA-
TIENTS WITH MULTIPLE MYELOMA
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Champlin, R.E.1, Giralt, S.A.1 1UT-MD Anderson Cancer Center,
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Background: Several trials have shown that autologous stem cell
transplantation is superior to conventional therapy in terms of
complete response (CR) rate, event-free survival (EFS) and overall
survival (OS). This treatment, however, is generally limited to
patients younger than 65 due to concerns about excessive toxicity
and treatment-related mortality (TRM) in older patients. Previous
reports have shown that age alone should not exclude patients from
high-dose therapy, as long as they fulﬁll other eligibility criteria. In
this report we analyzed the safety and efﬁcacy of high-dose che-
motherapy (HDT) and autologous transplant in patients with MM
who were  70 years at the time of autotransplant.
Methods: Twenty-six patients (16 males, 10 females) with a
median age of 72 (range 70-79) underwent HDT and an autograft
between July 1999 and October 2005. The preparative regimen
was melphalan 200 mg/m2 in 19 patients (73%), melphalan 180
mg/m2 in 6 and melphalan140 mg/m2 in 1 patient. Of the 26
patients, 12 were receiving ﬁrst remission consolidation, 7 had
primary refractory disease and 7 had relapsed disease. Clonal cy-
togenetic abnormalities were present in 5 patients (19%).
Results: Twenty-two of the 26 patients were alive after a median
follow up of 25 months (range 8-74). Responses (complete 
partial response) were seen in 20 patients (77%), ﬁve (19%) of
which were complete responses. Median PFS was 24 months and
median OS has not been reached yet. 100-day TRM was 0%.
Median times to absolute neutrophil count of 0.5  109/l and
platelets 20  109/l were 10 and 10 days, respectively. Three-
year PFS and OS were 39% and 65%, respectively. A serum
albumin 3.5 g/dl (p0.02), abnormal cytogenetics at transplant
(p0.05) and 2 prior chemotherapy regimens (p0.02) were
associated with a shorter PFS. Patients transplanted with relapsed
disease had a shorter OS (p0.0004). ISS stage, 2 microglobulin
level, lactic dehydrogenase (LDH) level, abnormal cytogenetics,
CCI or HCT-CI at the time of transplant did not emerge as
signiﬁcant predictors of PFS or OS in this group of patients.
Conclusions: HDT and autologous transplant is safe and feasi-
ble in selected patients70 years of age. Patients transplanted with
relapsed disease had a shorter OS.
21
TOTAL MARROW IRRADIATION (TMI) USING HELICAL TOMOTHERAPY:
DOSIMETRIC ANALYSIS DEMONSTRATES REDUCED ORGAN DOSES
WHICH CORRELATE WITH REDUCTION IN ACUTE TOXICITIES AND
PREDICT FOR ESCALATION OF DOSE TO TARGET MARROW BEYOND
THAT ACHIEVABLE BY STANDARD TBI
Wong, J.Y.C.1, Liu, A.1, Schultheiss, T.1, Parker, P.1, Krishnan, A.1,
Sahebi, F.1, Karanes, C.1, Spielberger, R.1, Rosenthal, J.1, Forman, S.1,
Somlo, G.1 1City of Hope Cancer Center, Duarte, CA.
TBI dose escalation has been difﬁcult due to associated organ
toxicities. We recently demonstrated the feasibility of using Tomo-
therapy (an image guided IMRT delivery system) to deliver a more
targeted dose of TBI to sites of greatest tumor burden (bone/marrow)
with reduced dose to normal organs in a patient with multiple my-
eloma. This study provides a dosimetric analysis of target bone/
marrow and normal organ doses from the ﬁrst 13 patients treated, and
details of set-up and delivery using this novel system.
Twelve patients with multiple myeloma (MM) were treated with
Mel (200 mg/m2) followed 6 weeks later by TMI as part of a tandem
autologous transplant Phase I/II trial. Total TMI doses were 10 Gy (3
patients), 12 Gy (4 patients), 14 Gy (3 patients) and 16 Gy (2 patients)
delivered 2 Gy QD or BID over 5 days. One patient with AML was
treated with TMITLI to 12 Gy (1.5 Gy BID)  concomitant
Flu/Mel on a separate trial. Treatment time was 50 minutes, jaw size
2.5 cm, and pitch 0.45. Patients were treated supine with full body
immobilization. Whole body CT imaging was performed by the
Tomotherapy unit prior to each fraction to provide 3D alignment of
patient anatomy to the intended target regions.
Median organ doses ranged from 15-65% that of the target bone/
marrow dose. The degree of organ sparing was similar for all patients
despite differences in thickness and habitus. Of the 84 TMI treatment
sessions delivered, only one was temporarily interrupted due to nausea
and vomiting. In the immediate post-TMI period, all MM patients
experienced grade 1-2 nausea, with half experiencing no vomiting.
Erythema, diarrhea, and mucositis were infrequent and grade 1-2.
The AML patient experienced grade 2 nausea, grade 1 vomiting and
grade 3 mucositis. This compares favorably to acute symptoms asso-
ciated with large ﬁeld hemibody RT or standard TBI.
This study conﬁrms the feasibility of using Tomotherapy to deliver
TMI. Dosimetric studies demonstrated reduced organ doses and
predicted for reduced toxicities. Clinical results conﬁrmed these pre-
dictions. The techniques used can be adapted bymost centers with the
technology. This study predicts for the ability to dose escalate to a
level where normal organs receive comparable standard TBI doses
with target regions receiving a signiﬁcantly higher dose than achiev-
able with TBI, offering the potential for improved outcomes in pa-
tients with hematologic malignancies.
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EX-VIVO EXPANSION (EvE) OF PREVIOUSLY CRYOPRESERVED CORD
BLOOD (CB) INTO NATURAL KILLER (NK) CELLS WITH ENHANCED
AML AND NEUROBLASTOMA CYTOTOXICITY: POTENTIAL ROLE OF CB
NK CELLS IN ADOPTIVE CELLULAR IMMUNOTHERAPY (ACI)
Ayello, J.1, Satwani, P.1, van de Ven, C.1, Shereck, E.1, Roman, E.1,
Wapner, R.J.2, Cairo, M.S.1,3,4
1
Department of Pediatrics; 2Obstetrics/
Gynecology; 3Medicine; 4Pathology, New York-Presbyterian, Columbia
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CD56 NK subsets exhibit differential NK receptors (NKR)
such as cytotoxicity proﬁles including killer-Ig-like receptors
(KIR), C-lectin (NKG2) and natural cytotoxicity receptors (NCR)
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